Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?

Sue Martya The Dow Chemical Company, Midland, MI, USA

Manon Beekhuijzenb Charles River Laboratories, Den Bosch, The Netherlands

Alex Charltonc Syngenta, Jealott’s Hill, Bracknell, United Kingdom

Nina Hallmarkd Bayer AG, Monheim, Germany

Bethany R. Hannase Corteva Agriscience, Newark, DE, USA

Sylvia Jacobif Albemarle, Louvain-la-Neuve, Belgium

Stephanie Melching-Kollmussg BASF SE, Ludwigshafen, Germany

Ursula G. Sauerh Scientific Consultancy – Animal Welfare, Neubiberg, Germany

Larry P. Sheetsi Bayer Crop Science, Chesterfield, MO, USA

Volker Straussg BASF SE, Ludwigshafen, Germany

Daniel Urbischg BASF SE, Ludwigshafen, Germany

Philip A. Bothamc Syngenta, Jealott’s Hill, Bracknell, United Kingdom

Bennard van Ravenzwaayg BASF SE, Ludwigshafen, GermanyCorrespondence[email protected]

Your download is now in progress and you may close this window